INEP medical s.r.o. — Clinical Trial Site

36 Registered trials

14 Currently recruiting

Organisation

INEP medical s.r.o.

Location

Prague, Czechia

Identifier

ORG-100043271

Address

Soubezna II 664 29, 158 00, Czechia

Departments

203003: INEP medical s.r.o.
Chronic pain
INEP MedicaL s.r.o.
Institut neuropsychiatrické péče
Institute of Neuropsychiatric Care
n/a
NA
Neurologické oddělení, klinická hodnocení
Neurology Department
Oddeleni psychiatrie
Private practice
psychiatrická ambulance
Psychiatry

Clinical trials at this site (36)

Search interface

A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as … Ended

2024-511557-21-00 Major Depressive Disorder (MDD) with Moderate-to-severe 5 2024-11-14
A dose-finding trial with LU AG90222 in adults with migraine who have not been helped by prior preventative treatments. Ended

2023-508821-28-00 Migraine 4 2024-08-14
A study to test different doses of BI 1569912 in people with depression who take anti-depressive medicine Ended

2023-507942-10-00 Major depressive disorder 4 2024-07-31
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 versus Placebo in Participants wit… Ended

2023-506335-15-00 Major Depressive Disorder 5 2024-07-18
An adaptive, randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of RL-007 in the treatment of cognitive … Ended

2023-506570-12-01 Cognitive disorder 4 2024-06-13
Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended

2023-507358-34-00 For the treatment of patients with chronic non-specific 4 2024-02-13
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine… Ended

2022-501172-25-00 Chronic and Episodic Migraine 5 2024-01-17
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Ended

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in… Ended

2023-510047-37-00 Treatment-resistant depression (TRD) 4 2023-03-30
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29
Phase 3 Open label clinical trial with oral Atogepant for the prevention of migraine Ended

2023-507096-21-00 Chronic or Episodic Migraine (Migraine without aura, mi 5 2021-08-16